SCI

14 July 2024

Interruption of the intratumor CD8+ T cell: Treg crosstalk improves the efficacy of PD-1 immunotherapy

(IF: Cancer Cell, 48.8)

  • Geels SN, Moshensky A, Sousa RS, Murat C, Bustos MA, Walker BL, Singh R, Harbour SN, Gutierrez G, Hwang M, Mempel TR, Weaver CT, Nie Q, Hoon DSB, Ganesan AK, Othy S, Marangoni F. Interruption of the intratumor CD8+ T cell: Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell. 2024 Jun 10;42(6):1051-1066.e7. 

  • Correspondence: f.marangoni@uci.edu

PD-1 blockade unleashes potent antitumor activity in CD8+ T cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen the response to immunotherapy. Tumor-Treg inhibition is a promising strategy to improve the efficacy of checkpoint blockade immunotherapy; however, our understanding of the mechanisms supporting tumor-Tregs during PD-1 immunotherapy is incomplete. Here, we show that PD-1 blockade increases tumor-Tregs in mouse models of melanoma and metastatic melanoma patients. Mechanistically, Treg accumulation is not caused by Treg-intrinsic inhibition of PD-1 signaling but depends on an indirect effect of activated CD8+ T cells. CD8+ T cells produce IL-2 and colocalize with Tregs in mouse and human melanomas. IL-2 upregulates the anti-apoptotic protein ICOS on tumor-Tregs, promoting their accumulation. Inhibition of ICOS signaling before PD-1 immunotherapy improves control over immunogenic melanoma. Thus, interrupting the intratumor CD8+ T cell: Treg crosstalk represents a strategy to enhance the therapeutic efficacy of PD-1 immunotherapy.

PD-1阻断可释放CD8+ T细胞中强大的抗肿瘤活性,但也可能促进免疫抑制性的T调节细胞(Treg),这可能会使得对免疫疗法的反应恶化。肿瘤 Treg 抑制是一种有前途的策略,可提高检查点阻断免疫疗法的疗效;然而,我们对支持PD-1免疫治疗期间肿瘤-Treg的机制的理解尚不完整。在这里,我们表明PD-1阻断会增加黑色素瘤和转移性黑色素瘤患者小鼠模型中的肿瘤 Treg。从机制上讲,Treg的积累不是由Treg内源性PD-1信号传导的内在抑制引起的,而是取决于活化的CD8+ T细胞的一个间接效应。CD8+ T细胞产生IL-2,并与小鼠和人类黑色素瘤中的Treg共定位。IL-2上调肿瘤-Treg上的抗凋亡蛋白ICOS,促进其积累。在PD-1免疫疗法之前抑制ICOS信号传导可改善对免疫原性黑色素瘤的控制。因此,打断肿瘤内CD8+ T细胞:Treg串扰代表了一种提高PD-1免疫疗法治疗效果的策略。